SALVATI, LORENZO
 Distribuzione geografica
Continente #
EU - Europa 938
NA - Nord America 752
AS - Asia 278
AF - Africa 6
SA - Sud America 2
Totale 1.976
Nazione #
US - Stati Uniti d'America 751
RU - Federazione Russa 545
IT - Italia 156
IE - Irlanda 105
SE - Svezia 86
HK - Hong Kong 81
SG - Singapore 62
CN - Cina 59
JO - Giordania 35
IN - India 27
CH - Svizzera 15
FI - Finlandia 13
CI - Costa d'Avorio 5
DE - Germania 5
GB - Regno Unito 4
JP - Giappone 3
KR - Corea 3
NL - Olanda 3
BR - Brasile 2
FR - Francia 2
ID - Indonesia 2
MM - Myanmar 2
UA - Ucraina 2
VN - Vietnam 2
CA - Canada 1
GR - Grecia 1
RO - Romania 1
SC - Seychelles 1
TR - Turchia 1
TW - Taiwan 1
Totale 1.976
Città #
Dublin 105
Ashburn 88
Fairfield 87
Chandler 83
Hong Kong 55
Moscow 51
Singapore 48
Woodbridge 42
Houston 36
Cambridge 35
Wilmington 31
Florence 29
Altamura 26
Lawrence 26
Mumbai 26
Seattle 22
Buffalo 19
Princeton 19
Shanghai 16
Washington 15
Bern 14
Kent 14
New York 14
Medford 11
Boston 10
Helsinki 10
Oristano 9
San Diego 9
Santa Clara 9
Beijing 8
Ann Arbor 7
Sant'elpidio A Mare 6
Siena 6
West Jordan 6
Abidjan 5
Norwalk 5
Boardman 4
Campi Bisenzio 4
Napoli 4
Rome 4
Bremen 3
Cecina 3
Fiesole 3
Hillsboro 3
Kin 3
Lappeenranta 3
Luni 3
Pisa 3
Redmond 3
Seoul 3
Yubileyny 3
Avellino 2
Bari 2
Chengdu 2
Falls Church 2
Ho Chi Minh City 2
Laurel 2
Livorno 2
Los Angeles 2
Paris 2
Redwood City 2
Rio de Janeiro 2
San Giovanni Valdarno 2
Yangon 2
Abenberg 1
Catanzaro 1
Cedar Knolls 1
Chicago 1
Fontebuona 1
Hangzhou 1
Henderson 1
Hsinchu 1
Jacksonville 1
Leawood 1
London 1
Mahé 1
Milan 1
Modena 1
Monmouth Junction 1
Monteriggioni 1
Naples 1
Peristerion 1
Pune 1
San Mateo 1
Scarperia e San Piero 1
Sesto Fiorentino 1
Signa 1
Soci 1
Specchia 1
Tianjin 1
Torino 1
Toronto 1
Utrecht 1
Totale 1.106
Nome #
The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study 127
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 119
Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients 106
Clinical and dermoscopic features of lichenoid keratosis: A retrospective case study 105
Clinical and Dermoscopic Features of Vulvar Melanosis over the Last 20 Years 90
Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab 86
Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab 78
Prompt Predicting of Early Clinical Deterioration of Moderate-to-Severe COVID-19 Patients: Usefulness of a Combined Score Using IL-6 in a Preliminary Study 76
A clinical, pathological and immunohistochemical series of 9 cases of primary cutaneous apocrine carcinomas of the head and neck 71
Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals 69
Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection 67
First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19 63
SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron 59
Spectrum of Fibrotic Lung Diseases 57
A gendered magnifying glass on COVID-19 56
Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization 51
SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes: implications for booster strategies 49
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 45
Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications 44
Clonally expanded PD-1-expressing T cells are enriched in synovial fluid of juvenile idiopathic arthritis patients 43
Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion 43
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 41
Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis 38
Variants Disrupting CD40L Transmembrane Domain and Atypical X-Linked Hyper-IgM Syndrome: A Case Report With Leishmaniasis and Review of the Literature 38
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent 37
“Adrenaline junkie”: a case report of repeated use of epinephrine 36
From Emollients to Biologicals: Targeting Atopic Dermatitis 35
Disseminated nocardiosis and anti-GM-CSF antibodies 35
Fourth Dose of mRNA COVID-19 Vaccine Transiently Reactivates Spike-Specific Immunological Memory in People Living with HIV (PLWH) 35
Alarming inflammation: The TGFβ1–Nrp1 pathway upregulates the IL-33 axis in lung ILC2s 32
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients 32
Thymic stromal lymphopoietin and alarmins as possible therapeutical targets for asthma 32
Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients 29
Musculin does not modulate the disease course of Experimental Autoimmune Encephalomyelitis and DSS colitis 27
Presentation and progression of MPO-ANCA interstitial lung disease 25
Optimization of the diagnosis and characterization of gibberellin-regulated protein sensitization: An Italian cohort study 22
Pembrolizumab-associated anti-MDA5 dermatomyositis in a patient with lung cancer: a first case report 14
Therapeutical Targets in Allergic Inflammation 13
Totale 2.025
Categoria #
all - tutte 9.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.907


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202064 0 0 0 4 8 12 8 8 8 4 8 4
2020/2021215 4 2 21 47 30 10 2 16 21 16 26 20
2021/2022171 7 15 7 5 11 17 4 12 11 7 29 46
2022/2023511 35 95 29 26 25 83 68 29 66 11 23 21
2023/2024386 7 26 48 21 27 63 10 69 8 53 34 20
2024/2025670 68 215 106 281 0 0 0 0 0 0 0 0
Totale 2.025